INTERVIEW: Glenmark on the promise of emerging markets and niche US generics

Glenmark's chairman and managing director, Glenn Saldanha, believes that key emerging markets now caught up in a vortex of regulatory change will deliver their promise in the long run, although the short term could be fraught with pain.

Glenmark's chairman and managing director, Glenn Saldanha, believes that key emerging markets now caught up in a vortex of regulatory change will deliver their promise in the long run, although the short term could be fraught with pain.

In a freewheeling interview with Scrip, Mr Saldanha referred to how market growth in Russia and India had tapered significantly...

More from Musculoskeletal

More from Therapy Areas

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By 

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By 

Multi-blockbuster falls short in a giant cell arteritis study.